A First-in-human, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of GLPG4059 in Adult, Healthy, Male Subjects
Latest Information Update: 12 May 2021
At a glance
- Drugs GLPG 4059 (Primary) ; GLPG 4059 (Primary)
- Indications Diabetes mellitus; Metabolic disorders
- Focus Adverse reactions; First in man
- Sponsors Galapagos NV
- 07 May 2021 Status changed from recruiting to discontinued(The study was stopped because Development of compound has been stopped ).
- 08 Oct 2020 New trial record